Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dilafor AB
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Finland, Sweden
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Pre-Eclampsia|Pregnancy Outcomes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
PPL20 | P2 |
Active, not recruiting |
Pre-Eclampsia |
2023-03-30 |
|
PPL17 | P2 |
Completed |
Pregnancy Outcomes |
2023-02-14 |
24% |
2019-000620-17 | P2 |
Active, not recruiting |
Unknown |
2022-05-08 |